구조모아 (StructureMoa)항암 chemical structure spider web
방문향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 15건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab | 신뢰 높음 | NCT02453620 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy). | 보통 | NCT02827877 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival | 보통 | NCT04003649 |
| 2026년 9월 | Kadcyla (ado-trastuzumab emtansine / T-DM1) | N/A | Active, not recruiting | Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response; Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response | 보통 | NCT02226276 |
| 2026년 9월 | Ipilimumab | Phase 2 | Active, not recruiting | Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab | 보통 | NCT03355976 |
| 2026년 9월 | Disitamab Vedotin (RC48) | Phase 1, Phase 2 | Recruiting | dose-limiting toxity; ORR（Objective Response Rate） | 보통 | NCT05403242 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03504397 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Number of Participants With Complete Pathologic Response (pCR) | 신뢰 높음 | NCT03879577 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03653507 |
| 2026년 9월 | Cemiplimab | — | Recruiting | Incidence of treatment-related sexual dysfuction in male patients with ANSCLC | 신뢰 높음 | NCT06532149 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Recommended phase II dose (Phase I); Incidence of adverse events (Phase I) | 신뢰 높음 | NCT02496208 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Pathological Complete Response rate (pCR) | 신뢰 높음 | NCT04172259 |
| 2026년 9월 | Ivonescimab | Phase 2 | Not yet recruiting | 6-month-PFS rate | 보통 | NCT06991491 |
| 2026년 9월 | Enhertu (trastuzumab deruxtecan) | — | Enrolling by invitation | Complete response (CR: no emesis and no rescue medication) | 신뢰 높음 | NCT07132749 |
| 2026년 9월 | Obinutuzumab | N/A | Recruiting | Progression-free survival rate at 24 months | 신뢰 높음 | NCT05950997 |
Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab
NCT02453620Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy).
NCT02827877Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival
NCT04003649Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response; Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
NCT02226276Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab
NCT03355976dose-limiting toxity; ORR（Objective Response Rate）
NCT05403242Progression Free Survival (PFS)
NCT03504397Number of Participants With Complete Pathologic Response (pCR)
NCT03879577Progression Free Survival (PFS)
NCT03653507Incidence of treatment-related sexual dysfuction in male patients with ANSCLC
NCT06532149Recommended phase II dose (Phase I); Incidence of adverse events (Phase I)
NCT02496208Pathological Complete Response rate (pCR)
NCT041722596-month-PFS rate
NCT06991491Complete response (CR: no emesis and no rescue medication)
NCT07132749Progression-free survival rate at 24 months
NCT05950997향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 15건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab | 신뢰 높음 | NCT02453620 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy). | 보통 | NCT02827877 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival | 보통 | NCT04003649 |
| 2026년 9월 | Kadcyla (ado-trastuzumab emtansine / T-DM1) | N/A | Active, not recruiting | Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response; Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response | 보통 | NCT02226276 |
| 2026년 9월 | Ipilimumab | Phase 2 | Active, not recruiting | Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab | 보통 | NCT03355976 |
| 2026년 9월 | Disitamab Vedotin (RC48) | Phase 1, Phase 2 | Recruiting | dose-limiting toxity; ORR（Objective Response Rate） | 보통 | NCT05403242 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03504397 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Number of Participants With Complete Pathologic Response (pCR) | 신뢰 높음 | NCT03879577 |
| 2026년 9월 | Vyloy (zolbetuximab) | Phase 3 | Active, not recruiting | Progression Free Survival (PFS) | 신뢰 높음 | NCT03653507 |
| 2026년 9월 | Cemiplimab | — | Recruiting | Incidence of treatment-related sexual dysfuction in male patients with ANSCLC | 신뢰 높음 | NCT06532149 |
| 2026년 9월 | Ipilimumab | Phase 1 | Active, not recruiting | Recommended phase II dose (Phase I); Incidence of adverse events (Phase I) | 신뢰 높음 | NCT02496208 |
| 2026년 9월 | Herceptin (trastuzumab) | Phase 2 | Active, not recruiting | Pathological Complete Response rate (pCR) | 신뢰 높음 | NCT04172259 |
| 2026년 9월 | Ivonescimab | Phase 2 | Not yet recruiting | 6-month-PFS rate | 보통 | NCT06991491 |
| 2026년 9월 | Enhertu (trastuzumab deruxtecan) | — | Enrolling by invitation | Complete response (CR: no emesis and no rescue medication) | 신뢰 높음 | NCT07132749 |
| 2026년 9월 | Obinutuzumab | N/A | Recruiting | Progression-free survival rate at 24 months | 신뢰 높음 | NCT05950997 |
Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab
NCT02453620Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy).
NCT02827877Incidence of adverse events; Dose-limiting toxicity (DLT); Feasibility (neoadjuvant therapy); Feasibility (adjuvant therapy); Overall Survival
NCT04003649Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response; Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
NCT02226276Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab
NCT03355976dose-limiting toxity; ORR（Objective Response Rate）
NCT05403242Progression Free Survival (PFS)
NCT03504397Number of Participants With Complete Pathologic Response (pCR)
NCT03879577Progression Free Survival (PFS)
NCT03653507Incidence of treatment-related sexual dysfuction in male patients with ANSCLC
NCT06532149Recommended phase II dose (Phase I); Incidence of adverse events (Phase I)
NCT02496208Pathological Complete Response rate (pCR)
NCT041722596-month-PFS rate
NCT06991491Complete response (CR: no emesis and no rescue medication)
NCT07132749Progression-free survival rate at 24 months
NCT05950997